Secondary Logo

Journal Logo


Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C

Loulergue, Pierrea; Mir, Olivierb; Sogni, Philippec

Author Information
doi: 10.1097/QAD.0b013e3283519397

A 40-year-old man living with HIV since 1994 was diagnosed with acute hepatitis C virus (HCV) (genotype 3a) hepatitis in January 2011 after unprotected homosexual intercourse. His past history was otherwise unremarkable, and he denied using intravenous drugs. His co-medications at this time included raltegravir 400 mg b.i.d., darunavir 800 mg once daily, and ritonavir 100 mg daily. Hepatitis B virus serology was negative, and HIV viral load was below 20 copies/ml, with a CD4 cell count of 254/μl (18%). Liver function tests showed: serum glutamic oxaloacetic transaminase 61 UI/l, serum glutamic pyruvic transaminase 127 UI/l, bilirubin 9 μmol/l, gamma-glutamyl transferase 25 UI/l, alkaline phosphatases 63 UI/l, and HCV viral load was 68.106 IU/ml (7.84 log).

He was started on pegylated-interferon-α2a 180 μg/week and ribavirin 15 mg/kg/day on 23 March 2011. Immediate pretreatment HCV viral load was 5.2 106 IU/ml (6.72 log). The treatment was well tolerated with mild asthenia, and HCV viral load at week 4 of treatment was undetectable (<15 IU/ml or 1.2 log).

At week 12 of treatment, HCV viral load had risen to 11.2 106 IU/ml (7.05 log), with normal liver function tests. Pegylated-interferon injections were administered weekly at home by a nurse, excluding adherence issues. The patient admitted having had unprotected homosexual intercourse with a new sexual partner, but denied intravenous drug use at this time. Therefore, HCV genotype was determined again and was found to be 4a, 4c, 4d. The diagnosis of HCV super-infection was made, and the patient remained under pegylated-interferon and ribavirin until November 2011, in the absence of a validated therapeutic alternative. At week 12 of treatment, HCV viral load was 25 196 IU/ml (4.4 log).

The detection of multiple unique HCV viral strains is often designated as HCV mixed infection, and could result from simultaneous exposure or super-infection. HCV super-infection is defined as the presence of a new genotype, different to that observed at first.

Although re-infection following successful treatment for HCV can occur in up to 19% of patients [1], HCV super-infection during pegylated-interferon and ribavirin therapy is scarcely reported [2–5]. Most cases were described after blood transfusion, intravenous drug use, renal transplantation and colonoscopy [4]. To the best of our knowledge, the present case is the second documenting HCV super-infection caused by unprotected sexual intercourse [5]. Moreover, all cases but one reported super-infection with genotypes 1 and 3 [4].

Clinicians should be aware of the risk of HCV super-infection during pegylated-interferon and ribavirin therapy, and patients should be informed of this risk in case of unprotected sexual intercourse, given the severity of HIV–HCV co-infection.


Conflicts of interest

There are no conflicts of interest.


1. Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, et al.Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2011. doi: 10.1002/hep.24754.
2. Asselah T, Vidaud D, Doloy A, Boyer N, Martinot M, Vidaud M, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 2003; 52:900–902.
3. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39:1540–1543.
4. Blackard JT, Sherman KE. Hepatitis C virus coinfection and superinfection. J Infect Dis 2007; 195:519–524.
5. den Hollander JG, Rijnders BJ, van Doornum GJ, van der Ende ME. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. AIDS 2005; 19:639–640.
© 2012 Lippincott Williams & Wilkins, Inc.